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ABSTRACT 
INTRODUCTION: Exposure to environmental arsenic remains a major public health challenge. Human is exposed 
to arsenic from groundwater as a result of anthropogenic activities. Chronic exposure to inorganic arsenic has been 
linked with multiple medical conditions. Therefore, many agricultural countries have shifted the use of inorganic to 
the organic-based herbicide, monosodium methylarsonate (MSMA). However, with increasing numbers of chronic 
kidney disease of unknown etiology (CKDu), chronic exposure to herbicide is believed as one of the potential 
explanations. To date, studies on chronic effects of organic arsenic on the kidney are limited. Therefore, this study 
aimed to investigate the effect of chronic oral organic arsenic exposure on the rat’s kidney. MATERIALS AND 
METHOD: Thirty-six Sprague Dawley rats were randomly divided into treatment and its corresponding control 
groups according to the duration of observations either 2, 4 or 6 months. Both groups were subdivided into three 
subgroups, each with six animals per subgroup. The treatment groups were given oral MSMA at 63.20 mg/kg body 
weight, while control groups received distilled water. At the end of each duration, blood was collected for the renal 
profile, urine for neutrophil gelatinase-associated lipocalin (NGAL) marker, and kidney tissues were harvested for 
arsenic level measurement and histological analysis. RESULTS: Arsenic level and urinary NGAL were higher in all 
treatment groups than its corresponding control groups. Histological findings showed progressive pathological 
changes in the glomeruli and proximal tubules. CONCLUSIONS: Chronic oral exposure to low dose organic arsenic 
has demonstrated evidence of kidney injury in rats.   
 




Exposure to environmental arsenic remains a major 
public health challenge. World Health Organization 
(WHO) in 2018 had reported that 140 million people 
from 50 countries are exposed to arsenic above the 
recommended level of 10 µg/L.1 The major source of 
arsenic exposure was from groundwater contamination 
either from tube wells or shallow wells. Arsenic toxicity 
was suggested to be acquired through oral ingestion.2 
The main sources of arsenic contamination were coming 
from anthropogenic activities such as agricultural, 
industrial, and domestic activities. These activities 
include the usage of arsenic-based fertilisers, pesticides 
and herbicides, mining and refining, and efflux of 
industrial wastes into the water system.3 
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Chronic exposure to inorganic arsenic has been known 
to cause many medical conditions such as diabetes, 
hypertension, peripheral artery disease, and various 
tumour formation in the skin, lungs, urinary bladder, 
liver, and kidneys.4 Because of health complications that 
were caused by inorganic arsenic, the organic arsenical 
herbicides were introduced in the 1950s. Monosodium 
methyl arsenate (MSMA) becoming the most popular 
organic arsenical herbicide due to its low cost, 
effectiveness, and lower toxicity compared to lead 
arsenate, inorganic arsenic. Currently, MSMA is widely 
used for weed control in cotton and on turf and lawn.5  
Although the shifting to MSMA from inorganic arsenic 
was due to its less toxic chemical properties, some 
studies showed that organic arsenic could be as harmful 
as inorganic arsenic. For example, the methylated 
arsenic such as methylarsonous acid, MMA(III), is more 
toxic than inorganic arsenic species (iAsV).6 Oral 
exposure of MSMA may produce more toxic 
metabolites such as dimethyl arsenic (DMA) species in 
vivo, including monomethylarsonous acid (MMAIII) and 
dimethyl arsinic acid (DMA) radicals.7 DMA was found 
to enhance prostate carcinogenesis.8  
 
In agricultural countries i.e. Bangladesh and India, 
Chronic Kidney Disease of Unknown Etiology (CKDu) 
cases are on the rise. Many factors have been postulated 
as potential causes such as physical exertion, heat stress, 
water quality, and exposure to agrochemicals,9 but no 
definite cause has been confirmed. Exposure to 
agrochemicals such as MSMA has been identified to be 
one of the risk factors.10 Human studies on the chronic 
toxicity of arsenic and its effects on the kidneys are 
limited in providing some evidence to support the 
association between arsenic and kidney disease.11  Most 
studies were focused on the effect of inorganic arsenic 
over short term duration.12 Therefore, this study aimed 
to explore the effects of chronic low dose exposure of 
organic arsenic on the rats ’  k idneys.   
 
MATERIALS AND METHODS 
 
Ethical Approval  
 
The research protocol was approved by the Institutional 
Animal Care and Use Committee (IIUM/504/14/2/




A total of 36 Male-Sprague-Dawley rats of 
approximately 250g, aged 3-4 months old, were 
purchased from Universiti Putra Malaysia, Selangor. 
They were housed in polypropylene cages of two 
animals per cage. Throughout the study, they were 
maintained in standard experimental conditions of 12:12 
hours dark-light cycle, temperature between 25-27°C 
with adequate ventilation. The rats were acclimatised for 
7 days and accessed to standard rat chow (Gold Coin 
Feedmills Sdn. Bhd., Malaysia) and reverse osmosis 




Thirty-six rats (n=36) were equally divided into six 
groups, six animals each (n=6). Three treatment groups 
(TG 1, TG 2, and TG 3) and their corresponding 
control groups (CG 1, CG 2, and CG 3). The 
observation durations were 2,4 and 6 months. The 
durations, route of administration, and dosage of arsenic 
exposure were chosen based on the findings of the 
previous study.13 The 6-month exposure in rats is 




MSMA is an organic arsenic-based herbicide and 
pesticide. It was purchased from Ancom Corp Sdn. 
Bhd., Malaysia. The preparation was based on the 
previous study. 13 The dosage given to rats was 63.20 
mg MSMA per kilogram body weight via oral gavage.  
The actual arsenic content was approximately 7.30 mg, 
in mimicking arsenic exposure in humans as reported by 
Mandal & Suzuki, 2002.16 The dose was also below the 
WHO permissible limit of 10 μg/mL.17  
 
Arsenic Level Measurement  
 
A total of 36 samples section of kidney tissues taken, six 
samples from each group and measured for arsenic 
concentration. The samples were homogenised and 
digested with a mixture of nitric acid, hydrochloric acid, 
and hydrogen peroxide. Analysis of sample extracts            
was performed using Inductive Coupled Plasma                      
Mass Spectrometry (ICPMS) (ELAN9000, Perkinelmer, 
Canada).  
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Mean ± SD 
Treatment (n=6) 
Mean ± SD 
t df p-value 
2 months Sodium 118.8333 ± 58.2457 141.8333 ± 1.7224 -0.967 5.009 0.378 
  Potassium 4.1000 ± 2.0159 4.9167 ± 2.0159 -0.967 10 0.356 
  Chloride 83.0000 ± 40.6743 97.8333 ± 1.4720 0.893 5.013 0.413 
  Urea 6.1833 ± 3.0616 7.8833 ± 1.0265 -1.290 10 0.226 
  Creatinine 33.5000 ± 17.7285 43.5000 ± 9.3113 -1.233 10 0.249 
4 months Sodium 141.8333 ± 2.2286 142.0000 ± 2.8983 -0.112 10 0.913 
  Potassium 5.6500 ± 2.3072 4.7167 ± 0.4070 0.976 10 0.352 
  Chloride 98.1667 ± 3.7104 99.000 ± 1.2649 -0.521 10 0.614 
  Urea 8.4333 ± 1.0367 6.5667 ± 1.0152 3.151 10 0.010* 
  Creatinine 39.5000 ± 5.4314 39.5000 ± 5.9582 0.000 10 1.000 
6 months Sodium 141.5000 ± 1.7607 141.1667 ± 2.1370 0.295 10 0.774 
  Potassium 4.9500 ± 0.2510 4.8333 ± 0.6121 0.432 6.635 0.679 
  Chloride 98.5000 ± 1.6432 98.0000 ± 1.6733 0.522 10 0.613 
  Urea 7.7667 ± 0.5989 7.5000 ± 0.9230 0.594 10 0.566 
  Creatinine 41.6667 ± 7.8655 42.6667 ± 13.1098 -0.160 10 0.876 
Independentsample t-test. *p-value ≤ 0.05 is considered as statistically significant at a 95% confidence interval 
buffered formalin for at least 24 hours. Then underwent 
dehydration with graded concentrations of ethanol using 
an automated tissue processor (Leica TP 1020, Leica 
Biosystems Inc., Germany). The tissues were then 
embedded in liquid paraffin wax. Next, the tissues were 
trimmed and sectioned to 5 µm for Haematoxylin & 
Eosin (H&E) and periodic acid-Schiff (PAS) staining. 
The slides were captured with Digital Scanning System 





Data were analysed by using IBM SPSS Statistics for 
Windows, Version 21.0. (IBM Corp., Armonk, NY). 
Renal function test and NGAL marker were analysed by 
student t-test using Graphpad Prism version 8.0.0 for 
Windows (California, USA).  The histological changes 




Arsenic level in the kidney tissue of control and 
treatment groups 
 
The levels for control and MSMA treated groups are 
shown in Figure 1. The arsenic levels in treated groups 
were significantly higher compared to the corresponding 
control samples from each group duration. In 2-month 
groups, the arsenic level in TG1 and CG1 were 98.67 ± 
Table I. Comparison of the renal function test between the control and the MSMA treated groups.  
Renal Function Test 
 
The blood samples were collected from the orbital sinus 
under inhalation of diethyl ether anaesthesia. The blood 
samples were then centrifuged at 4000 rpm (Centrifuge, 
Nüve, Turkey) for 10-minutes and collected sera were 
stored at -70°C. Before the measurement, the frozen 
sera were thawed and about 0.5 mL was used per sample 
cup. Each sample was measured in duplicate. The 
sample cups containing the serum were labelled and 
placed on the sample tray mounted on the Chemistry 
Analyzer (Cobas Integra 400, Roche Diagnostic, 





NGAL concentration in urine was measured using 
Lipocalin-2 (NGAL) Rat ELISA Kit (ab119602, Abcam) 
according to the manufacturer’s instruction. Four 
samples from each group (n=4) subjected to the 
analysis. The concentration of NGAL was proportional 
to the intensity of the coloured reaction product (450 
nm). All samples were analysed in triplicate. NGAL level 




The kidney tissue samples were processed for 
histological analysis. Samples were fixed in 10% neutral 
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Histopathological findings in renal corpuscles  
 
Glomerular structure in treated groups showed 
progressive pathological changes according to the 
duration of exposure to MSMA. In the control group, 
the glomeruli showed a normal glomerular appearance 
with a regular Bowman’s space (Figure 3A). In 2-month 
treated group (TG1), minimal changes were observed, 
such as hypercellularity of glomeruli and reduced 
Bowman’s space (Figure 3B). Meanwhile, in the 4-
month treated group (TG2), the glomeruli 
demonstrated atrophy with increased Bowman’s space 
(Figure 3C). Finally, in the 6-month treated group (TG 
3), the changes were more severe as glomeruli showed 
more severe atrophy, areas of sclerosis and marked 
increased in Bowman’s space (Figure 3D).  
Figure 1. The arsenic concentration in the kidney tissue of      
control and treatment groups at 2-month, 4-month, and 6-month 
durations (*p < 0.05).  
16.12 PPM and 2.43 ± 1.36 PPM, respectively. In               
4-month groups, TG 2 and CG2 were 99.52 ± 49.13 
PPM and 8.94 ± 2.84 PPM. While in 6-month groups, 
the concentration of arsenic in TG3 and CG3 were 
148.51 ± 65.65 PPM and 5.56 ± 3.71 PPM.  
 
Renal function test 
 
The mean renal function tests in control and MSMA 
treated groups for all durations are shown in Table I. 
There was no statistically significant difference in renal 
function test between control and MSMA treated 
groups for all durations. 
 
Urine Concentration of NGAL in Control and MSMA 
Treated Groups 
 
Generally, MSMA treated groups (TG 1, TG 2 and TG 
3) showed higher levels of NGAL concentration 
compared to control groups (Figure 2). However, only 
TG 2 (3141.92 ± 346.53 pg/mL), showed a significantly 
higher level in comparison to its control, CG 2 (2499.67 
± 198.64 pg/mL) (P = 0.018).  
Figure 2 Comparison of the urinary level of NGAL in control and 
MSMA treated groups in 2-month, 4-month, and 6-month         
durations. Results presented as mean (SD).  Independent sample         
t-test. *p-value ≤ 0.05 is considered as statistically significant at a 
95% confidence interval.  
Figure 3 Photomicrograph of kidney section showing renal 
corpuscles of each group.  (A) Control group showing normal 
morphology of glomerulus (arrow) and Bowman’s space (star). 
(B) TG 1 showing glomerular hypercellularity (arrow) and       
reduced Bowman’s space (star). (C) TG 2 showing glomerular 
atrophy (arrow) with increased Bowman’s space (star). (D) TG 3 
showing marked glomerular atrophy and sclerosis (arrow) with a 
marked increased in Bowman’s space (star). (H&E stain, X400) 
Histopathological findings in proximal convoluted 
tubules 
 
In control groups, the tubules appeared normal with 
clear brush border (Figure 4 A). Proximal convoluted 
tubules (PCT) showed progressive changes in             
treated groups. In TG 1, no apparent changes were 
demonstrated and tubules were also normal (Figure 4 B). 
In TG 2, the lumina of tubules were dilated, some 
detachment of nuclei which were displaced into the 
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histological changes, which showed the most 
pathological changes in the 6-month treatment group.  
 
Renal function test is one of the commonly used 
investigations in evaluating the kidney function. Serum 
urea and creatinine are most widely accepted parameters 
in the assessment of chronic kidney disease. These 
metabolic waste products are normally excreted by the 
kidneys. 21 In the case of kidney disease, there will be an 
increase in urea, creatinine and potassium which indicate 
damaged renal function. The present study showed that 
chronic exposure of low dose organic arsenic in the rats 
exhibited no significant differences in the renal profile as 
compared to the control groups despite progressive 
changes observed in the glomeruli and tubules of treated 
animals. A previous study done by Mohssen showed that 
histological changes appeared earlier than derangement 
in renal function22.  It is reported that an elevated serum 
creatinine can be detected if there is a loss of about 50% 
of kidney function. Therefore, a rise in the serum 
creatinine level is a late marker of acute kidney injury. Its 
level could be more pronounced later in chronic kidney 
disease when there is a substantial reduction in the 
glomerular filtration rate or obstruction to urine 
elimination. 23, 24 Thus, we recommend future studies to 
prolong the exposure duration, which expected more 
extensive damage to the kidney and might result in 
derangement of renal function.  
 
The urine NGAL is used as kidney injury biomarker to 
detect early kidney injury. In the kidney, NGAL is 
mainly secreted from the loop of Henle and collecting 
ducts. It is expressed by tubular epithelial cells in 
response to injury and tubulointerstitial damage.25 The 
level of NGAL is also associated with the degree of 
kidney dysfunction and very useful to monitor the 
outcome of kidney injury.26 The urinary levels of           
NGAL in treatment groups were relatively at higher 
concentration, in all durations. The significantly higher 
level at four months duration is corresponding with the 
early histological appearance of tubular damage. In two 
months and six months treatment groups, the levels 
were not significantly higher compared to control. This 
could be due to a wider biological variation in urinary 
NGAL compared to plasma NGAL which reported as 
its limitations. 27-29 Nevertheless, the finding in this study 
suggests that a higher level of urinary NGAL biomarker 
could be more sensitive than serum renal function test as 
lumina and discontinuity of brush border were observed 
(Figure 4 C). In TG 3, the lumina showed more obvious 
dilatation, with minimal nuclei located close to the basal 
membrane and the lumina were filled with a hyaline cast 
(Figure 4 D).  
Figure 4 Photomicrograph of kidney section showing the 
tubules. (A) Control group, showing normal morphology of 
proximal tubules, in-situ nuclei with clear brush border (arrow). (B) 
TG 1 is also showing normal proximal tubules (arrow). (C) TG 2 
showing dilated lumen of PCT (star), detachment of nuclei, and 
discontinuity of brush border (arrow). (D) TG 3 shows PCT with 
marked dilatation of the lumen filled with hyaline cast fluid (star), 
diminished brush border, and flattening of tubular epithelial cells 
(arrow). (PAS stain, X400) 
DISCUSSION 
 
Measurement of arsenic level in the tissue is important to 
confirm the arsenic accumulation in the kidney tissues. 
The study showed that the arsenic levels in the kidney 
tissues were found to be higher in all treatment groups as 
compared to the corresponding control groups of the 
same durations. The result revealed that the arsenic level 
was markedly higher in the 4-month treatment group as 
compared to the 2-month and 6-month treatment 
groups. In the chronic exposure of arsenic, arsenic was 
reported to reaccumulate in the proximal tubules.18 The 
total arsenic accumulation in the proximal tubules 
depends on the dosage and duration of exposure.19,20 
The current study showed that the arsenic level was 
higher in TG 2 than TG1. Therefore, the longer the 
period of exposure, the more arsenic accumulated in the 
kidney tissues and more damage to the kidney. The 
levels of arsenic were in agreement with the progressive 
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an indicator for early kidney injury.  
 
Histological analysis remains the gold standard in 
diagnosing kidney injury. 24 The pathological changes in 
nephrotoxicity injury are mainly focal and segmental 
lesions. 30 Previous studies on metal nephrotoxicity, 
which include arsenic, were primarily focussed on the 
proximal tubules as the major site of injury. This is 
because reaccumulation and reabsorption of 
nephrotoxicants occur at the proximal tubules. 31 
However, few studies also showed that glomerulus 
might also vulnerable in arsenic exposure besides 
proximal tubules. Involvement of the glomerulus is 
mainly at the glomerular basement membrane and 
podocyte.32,33 In this study, the initial injury at 2-month 
group was minimal, which limited to the glomeruli. The 
glomeruli only showed initial changes such as 
hypercellularity due to mesangial expansion. Meanwhile, 
as the duration of exposure progresses, in 4 and 6-
month treatment groups, the histological changes 
started to show progressive kidney injury changes such 
as glomerular atrophy, sclerosis and tubular damage. As 
the injury worsened, there were necrosis and 
detachment of epithelial cells of PCT. The cells 
disintegrated and leaving the cell debris in the lumen. 
Later, obstructing the tubular lumen, which gives rise to 
accumulation of hyaline cast and dilatation of tubular 
lumen. These findings suggest that, in chronic low dose 





This study demonstrated the evidence of the 
detrimental effects of chronic low dose organic arsenic 
exposure on the kidney. The injury appeared to affect 
both glomerular and tubular structures. However, the 
exact mechanism of injury requires future studies to 
mapping out the pathway of kidney injury. Hence, 
further intervention is possible to prevent the 
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